Interdisciplinary Prostate Cancer Congress | Conference

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

Gomella Discusses Optimizing Sipuleucel-T in mCRPC

March 16th 2015

In an interview with OncLive, Leonard G. Gomella discusses the benefits, limitations, and considerations of sipuleucel-T for patients with prostate cancer.

Dr. Benson on Challenges of Active Surveillance for Prostate Cancer

March 16th 2015

Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.

Dr. Dreicer on Sequencing Therapies for Patients with Prostate Cancer

March 16th 2015

Robert Dreicer, MD, MS, FACP, FASCO, Division of Hematology and Oncology, Department of Medicine, University of Virginia School of Medicine, discusses sequencing therapies in prostate cancer.

PD-1 Pathway Combos Lead the Way in RCC Immunotherapy

March 16th 2015

The prospects for combining anti–PD-1 pathway agents with other checkpoint blockade inhibitors or with agents that target angiogenesis are among the most promising immunotherapy approaches under development for patients with metastatic renal cell carcinoma.

Dr. Higano on Radium-223 for mCRPC

March 16th 2015

Celestia S. Higano, MD, FACP, professor of medicine and urology, University of Washington, discusses radium-223 chloride and its efficacy for patients with metastatic castration-resistant prostate cancer (mCRPC).

Making Sense of the Prostate Cancer Screening Debate

March 14th 2015

Leonard G. Gomella, MD, told attendees at the 8th Annual IPCC that the decision to screen or not to screen for prostate cancer boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

Proceed With Caution Is the Message on Active Surveillance

March 14th 2015

Physicians should engage in careful patient selection before recommending active surveillance for prostate cancer, according to Mitchell C. Benson, MD.

Noted Astronaut Addresses Importance of Teamwork at Prostate Congress

March 14th 2015

In a similar fashion as astronauts, physicians can mitigate risks and improve outcomes with advanced planning and teamwork, four-time space shuttle commander Tom Henricks said during his keynote address at the Interdisciplinary Prostate Cancer Congress.

Dr. Richard Stock on Brachytherapy for Prostate Cancer

March 14th 2015

Richard Stock, MD, a professor of radiation oncology at the Icahn School of Medicine at Mount Sinai Hospital, talks about brachytherapy and its benefits for patients with prostate cancer.

Dr. Petrylak on Immunotherapy for Second-line Treatment in Bladder Cancer

March 14th 2015

Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center discusses the potential for immunotherapy for the treatment of bladder cancer.

With ADT in PC, Managing Side Effects Increasingly Important

July 1st 2014

Androgen-deprivation therapy (ADT) is a mainstay of treatment for prostate cancer in a number of settings, so managing its side effects is becoming increasingly important for urologists in collaboration with oncologists and primary-care physicians.

Radium 223 Option Hinges on Bony Disease Burden in mCRPC

June 5th 2014

As with other new therapies that have been approved in recent years for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), researchers are not entirely certain about how best to fit radium Ra 223 dichloride (Xofigo) into the emerging paradigm

Immunotherapies Promising But Still Challenging in CRPC

March 17th 2014

Increasing efficacy with immunotherapies in some cancers led to the strategy being deemed Breakthrough of the Year by Science magazine in 2013

Dr. Crawford on Rebiopsying for Prostate Cancer

March 17th 2014

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

Continue Screening for PSA But Treat Judiciously

March 17th 2014

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America's medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen's potential pitfalls.

Growing Role for Androgen-Targeting Therapies in CRPC

March 17th 2014

A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the management of CRPC.

Dr. Sartor Discusses PSA Testing for Prostate Cancer

March 17th 2014

Oliver Sartor, MD, board professor, cancer research, Tulane University, discusses the controversies surrounding PSA screening for prostate cancer.

7th Annual IPCC to Advance Multidisciplinary Care for Prostate Cancer

March 14th 2014

Insights about PSA screening, genomics, and what's new in the areas of imaging, antiandrogen therapy, radiation therapy, immunotherapy, and radiopharmaceuticals will be offered during the 7th Annual IPCC.

Dr. Crawford on Sipuleucel-T in Advanced Prostate Cancer

April 5th 2013

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the effectiveness of the immunotherapy sipuleucel-T as a treatment for men with advanced prostate cancer.